Literature DB >> 19194308

Costs of providing care for HIV-infected adults in an urban HIV clinic in Soweto, South Africa.

Neil Martinson1, Lerato Mohapi, Darryl Bakos, Glenda E Gray, James A McIntyre, Charles B Holmes.   

Abstract

BACKGROUND: As access to antiretroviral therapy (ART) in sub-Saharan Africa expands, estimates of the costs of initiating and maintaining patients on ART are important to program planning, budgeting, and cost-effectiveness analyses.
METHODS: Total costs of providing HIV care, including ART, in an urban, nongovernmental, adult clinic in Soweto, South Africa, were estimated from October 2004 through March 2005. Personnel costs were estimated using individuals' work time and salary, and for across-organization services (eg, information technology), a proportion of entire annual costs was applied. Utilization of medications, laboratories, and radiographic tests were estimated by a random sample of patient charts (10%) and applied to the entire cohort.
RESULTS: Nine hundred sixty-six adult patients received care during the study period (75% female, median age 34 years, median CD4 count at ART initiation: 109 cells/mm). Seventeen percent were stable on ART at entry, 61% initiated ART, and 22% did not receive ART over the course of the study. Mean cost of the entire program (in US $) was $92,388 per month, and mean per patient cost of care-regardless of ART treatment status-was $98.1 per month. Among adults on ART, costs were lowest for those already on ART ($119.0/month) and highest for those initiating ART ($209.7/month) in the first month and $130.0 the following month. Human resources and antiretrovirals each accounted for one third of overall costs.
CONCLUSIONS: The monthly cost of treating HIV-infected patients in an urban South African clinic was highest in the month of initiation and lower for stable patients, with costs driven predominantly by antiretrovirals and personnel.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19194308      PMCID: PMC3080749          DOI: 10.1097/QAI.0b013e3181958546

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

1.  South Africa's "rollout" of highly active antiretroviral therapy: a critical assessment.

Authors:  Nicoli Nattrass
Journal:  J Acquir Immune Defic Syndr       Date:  2006-12-15       Impact factor: 3.731

2.  Financial and economic costs of scaling up the provision of HAART to HIV-infected health care workers in KwaZulu-Natal.

Authors:  N Deghaye; R A Pawinski; C Desmond
Journal:  S Afr Med J       Date:  2006-02

3.  The evolving cost of HIV in South Africa: changes in health care cost with duration on antiretroviral therapy for public sector patients.

Authors:  Guy Harling; Robin Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2007-07-01       Impact factor: 3.731

4.  The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa.

Authors:  Sydney Rosen; Lawrence Long; Ian Sanne
Journal:  Trop Med Int Health       Date:  2008-07-08       Impact factor: 2.622

5.  Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.

Authors:  Olivia Keiser; Kathryn Anastos; Mauro Schechter; Eric Balestre; Landon Myer; Andrew Boulle; David Bangsberg; Hapsatou Touré; Paula Braitstein; Eduardo Sprinz; Denis Nash; Mina Hosseinipour; François Dabis; Margaret May; Martin W G Brinkhof; Matthias Egger
Journal:  Trop Med Int Health       Date:  2008-03-27       Impact factor: 2.622

6.  Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial.

Authors:  Nancy S Padian; Ariane van der Straten; Gita Ramjee; Tsungai Chipato; Guy de Bruyn; Kelly Blanchard; Stephen Shiboski; Elizabeth T Montgomery; Heidi Fancher; Helen Cheng; Michael Rosenblum; Mark van der Laan; Nicholas Jewell; James McIntyre
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

7.  Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial.

Authors:  Bertran Auvert; Dirk Taljaard; Emmanuel Lagarde; Joëlle Sobngwi-Tambekou; Rémi Sitta; Adrian Puren
Journal:  PLoS Med       Date:  2005-10-25       Impact factor: 11.069

8.  The cost-effectiveness of antiretroviral treatment in Khayelitsha, South Africa--a primary data analysis.

Authors:  Susan M Cleary; Di McIntyre; Andrew M Boulle
Journal:  Cost Eff Resour Alloc       Date:  2006-12-06
  8 in total
  24 in total

1.  Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.

Authors:  Ziad El-Khatib; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Alan Karstaedt; Salome Charalambous; Max Petzold; David Katzenstein; Lynn Morris
Journal:  AIDS       Date:  2010-07-17       Impact factor: 4.177

2.  Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country.

Authors:  Seth Inzaule; Chunfu Yang; Alex Kasembeli; Lillian Nafisa; Jully Okonji; Boaz Oyaro; Richard Lando; Lisa A Mills; Kayla Laserson; Timothy Thomas; John Nkengasong; Clement Zeh
Journal:  J Clin Microbiol       Date:  2012-12-05       Impact factor: 5.948

Review 3.  The state of health economic research in South Africa: a systematic review.

Authors:  Paul Gavaza; Karen L Rascati; Abiola O Oladapo; Star Khoza
Journal:  Pharmacoeconomics       Date:  2012-10-01       Impact factor: 4.981

Review 4.  Unit costs for delivery of antiretroviral treatment and prevention of mother-to-child transmission of HIV: a systematic review for low- and middle-income countries.

Authors:  Omar Galárraga; Veronika J Wirtz; Alejandro Figueroa-Lara; Yared Santa-Ana-Tellez; Ibrahima Coulibaly; Kirsi Viisainen; Antonieta Medina-Lara; Eline L Korenromp
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.981

5.  Superior outcomes and lower outpatient costs with scale-up of antiretroviral therapy at the GHESKIO clinic in Port-au-Prince, Haiti.

Authors:  Cynthia Riviere; Elizabeth Faust; Thane Miller; Eduard J Beck; Elaine Baruwa; Patrice Severe; Karine Severe; Claudia Thomas Riché; Rachelle Cassagnol; Sidney Atwood; Morgan Esperance; Lauren Webster; Pierre Cremieux; Jean W Pape; Serena P Koenig
Journal:  J Acquir Immune Defic Syndr       Date:  2014-08-01       Impact factor: 3.731

Review 6.  Epidemiology and challenges to the elimination of global tuberculosis.

Authors:  Mandeep S Jassal; William R Bishai
Journal:  Clin Infect Dis       Date:  2010-05-15       Impact factor: 9.079

7.  Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.

Authors:  Ziad El-Khatib; Allison K Delong; David Katzenstein; Anna Mia Ekstrom; Johanna Ledwaba; Lerato Mohapi; Fatima Laher; Max Petzold; Lynn Morris; Rami Kantor
Journal:  J AIDS Clin Res       Date:  2011-02-18

Review 8.  Is there scope for cost savings and efficiency gains in HIV services? A systematic review of the evidence from low- and middle-income countries.

Authors:  Mariana Siapka; Michelle Remme; Carol Dayo Obure; Claudia B Maier; Karl L Dehne; Anna Vassall
Journal:  Bull World Health Organ       Date:  2014-04-01       Impact factor: 9.408

9.  The cost of providing comprehensive HIV treatment in PEPFAR-supported programs.

Authors:  Nicolas A Menzies; Andres A Berruti; Richard Berzon; Scott Filler; Robert Ferris; Tedd V Ellerbrock; John M Blandford
Journal:  AIDS       Date:  2011-09-10       Impact factor: 4.177

10.  Topical gentian violet compared with nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1-infected participants.

Authors:  Pranab K Mukherjee; Huichao Chen; Lauren L Patton; Scott Evans; Anthony Lee; Johnstone Kumwenda; James Hakim; Gaerolwe Masheto; Frederick Sawe; Mai T Pho; Kenneth A Freedberg; Caroline H Shiboski; Mahmoud A Ghannoum; Robert A Salata
Journal:  AIDS       Date:  2017-01-02       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.